Hyderabad, Jan 21 (UNI) Dr Reddy's Laboratories today announced that it has entered into a settlement agreement with Novartis Pharma AG, which involves a stipulation of dismisal of lawsuits in the US relating to the Abbreviated New Drug Application (ANDA).
The ANDA was filed by Dr Reddy's for a generic version of Rivastigmine Tartrate capsules sold under the trade name Exelon.
Under the agreement terms, Dr Reddy's would not launch its generic capsules until sometime before the expiry of the Orange book patents claiming Rivastigmine.
The exact date of the launch and other terms of this agreement were confidential, a press release here said.
UNI AP VA ROY 1605